Gilead Sciences Inc. unveiled Phase II data for its farnesoid X receptor (FXR) agonist GS-9674 in non-alcoholic steatohepatitis (NASH) that raise doubts for its promise in that indication compared to other candidates from the same class, but Gilead’s drug fared better in a primary sclerosing cholangitis (PSC) trial, showing improvements in liver biochemistry and markers of cholestasis.
A competing NASH candidate, Intercept Pharmaceuticals Inc.'s obeticholic acid (OCA), showed the ability to reduce both fibrosis and steatosis in the Phase II FLINT trial, although increased lipid levels were seen in the same study. (Also see "Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate" - Pink Sheet, 17 November, 2014.) In Phase II data presented at the American Association for the Study of Liver Disease meeting Nov
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?